Amylyx Pharmaceuticals
Filed with the SEC on · accession 0001193125-26-355696
AMLX filed a 424B5 (prospectus (offering)) with the SEC on Aug 18, 2026. Amylyx Pharmaceuticals filed a preliminary prospectus supplement for a $350 million underwritten public offering of common stock. The stock moved +63.8% by the first close after the filing.
Amylyx Pharmaceuticals filed a preliminary prospectus supplement for a $350 million underwritten public offering of common stock. The offering is being managed by Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital.
Close before
$21.43
Aug 17, 2026
First close after
+63.84%
$35.11
5 trading days
+78.02%
$38.15
Since filing
+28.88%
$27.62
✦ Ask GOAX AI about this filing — what it means for AMLX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AMLX?
Click hereAMLX filed a 424B5 (Secondary offering). Amylyx Pharmaceuticals filed a preliminary prospectus supplement for a $350 million underwritten public offering of common stock. The offering is being managed by Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital.
New shares dilute existing holders and are often sold at a discount to the market price.
The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B5 (prospectus (offering)): The final terms of an offering of shares or bonds.
AMLX closed at $21.43 before the filing and $35.11 on Aug 18, 2026 (+63.84%). Five trading days later: $38.15 (+78.02%).
Get alerts when AMLX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days